Table 49 (abstract A620). General patient characteristics
Overall | ICU mortality | 6 month mortality | |||||
|---|---|---|---|---|---|---|---|
Survivors | Exitus | p | Survivors | Exitus | p | ||
Sex (% of women) | 28% | 30,77% | 25% | 0,748 | 28,57% | 27,78% | 0,968 |
Age (years) | 44,72±16,32 | 49,85±15,42 | 39,17±16,32 | 0.0969 | 49,43±18,27 | 42,89±16,32 | 0,2498 |
Underlying disorder | |||||||
Lymphoblastic leukemia | 20% | 1 | 4 | 0,181 | 1 | 4 | 0,353 |
Non-Hodgkin lymphoma | 4% | 1 | 0 | 0 | 1 | ||
Multiple myeloma | 20% | 4 | 1 | 3 | 2 | ||
Marrow aplasia | 20% | 1 | 4 | 0 | 5 | ||
Lymphoblastic lymphoma | 4% | 1 | 0 | 1 | 0 | ||
AML | 16% | 2 | 2 | 1 | 3 | ||
Chronic Lymphocytic Leukemia | 4% | 1 | 0 | 0 | 1 | ||
Myelodysplastic syndrome | 8% | 2 | 0 | 1 | 1 | ||
Panmyelosis | 4% | 0 | 1 | 0 | 1 | ||
Type of HSTC | |||||||
Allogeneic | 79,17% | 7 (36,84%) | 12 (63,16%) | 0,043* | 3 (15,79%) | 16 (84,21%) | 0,0401* |
Autologous | 16,67% | 4 (100%) | 0 | 3 (75%) | 1 (25%) | ||
Microtransplant | 4,17% | 1 (100%) | 0 | 0 | 1 (100%) | ||
GHCD | 40,00% | 38,46% | 41,67% | 0,87 | 42,86% | 38,89% | 0,856 |
CMV | 35% | 20% | 50% | 0,16 | 0,00% | 46,67% | 0,058 |
APACHE II | 20,75±5,64 | 19,62±5,08 | 22,09±5,64 | 0,257 | 18,71±3,73 | 21,59±5,64 | 0,2514 |
SOFA | 8,38±3,98 | 6,54±3,89 | 10,55±3,98 | 0,0061* | 6,86±1,95 | 9±3,98 | 0,0787 |